Cargando…

Soluble Mesothelin-Related Peptides Levels in Patients with Malignant Mesothelioma

Soluble mesothelin-related peptides (SMRP) are a potential tumor marker for malignant mesothelioma. The aim of this study was to determine the differences in SMRP levels in patients with malignant mesothelioma before treatment and in various responses to treatment and to investigate whether SMRP lev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Franko, Alenka, Dolzan, Vita, Kovac, Viljem, Arneric, Niko, Dodic-Fikfak, Metoda
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2012
Materias:	Other
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3826705/ https://www.ncbi.nlm.nih.gov/pubmed/22377706 http://dx.doi.org/10.3233/DMA-2011-0866

Ejemplares similares

Fibulin-3 as a biomarker of response to treatment in malignant mesothelioma
por: Kovac, Viljem, et al.
Publicado: (2015)

Evaluation of Soluble Mesothelin-related Peptides and MSLN Genetic Variability in Asbestos-related Diseases
por: Goricar, Katja, et al.
Publicado: (2020)

Serum Survivin Levels and Outcome of Chemotherapy in Patients with Malignant Mesothelioma
por: Goričar, Katja, et al.
Publicado: (2015)

The Influence of Genetic Variability on the Risk of Developing Malignant Mesothelioma
por: Franko, Alenka, et al.
Publicado: (2018)

Serum Calretinin as a Biomarker in Malignant Mesothelioma
por: Zupanc, Cita, et al.
Publicado: (2021)

Inducible Nitric Oxide Synthase Genetic Polymorphism and Risk of Asbestosis
por: Franko, Alenka, et al.
Publicado: (2011)

Manganese and Extracellular Superoxide Dismutase Polymorphisms and Risk for Asbestosis
por: Franko, Alenka, et al.
Publicado: (2009)

The Role of Polymorphisms in Glutathione-related Genes in Asbestos-related Diseases
por: Franko, Alenka, et al.
Publicado: (2021)

NLRP3 and CARD8 polymorphisms influence risk for asbestos-related diseases
por: Franko, Alenka, et al.
Publicado: (2020)

The Influence of Genetic Variability of DNA Repair Mechanisms on the Risk of Malignant Mesothelioma
por: Levpuscek, Kristina, et al.
Publicado: (2019)

Genetic Polymorphisms in Aquaporin 1 as Risk Factors for Malignant Mesothelioma and Biomarkers of Response to Cisplatin Treatment
por: Senk, Barbara, et al.
Publicado: (2019)

The Influence of Genetic Variability in IL1B and MIR146A on the Risk of Pleural Plaques and Malignant Mesothelioma
por: Piber, Petra, et al.
Publicado: (2020)

The Influence of Gene-Gene and Gene-Environment Interactions on the Risk of Asbestosis
por: Franko, A., et al.
Publicado: (2013)

Clinical-pharmacogenetic models for personalized cancer treatment: application to malignant mesothelioma
por: Goričar, Katja, et al.
Publicado: (2017)

Sickness Presence among Disabled Workers at the University Medical Centre Ljubljana
por: ŠKERJANC, Alenka, et al.
Publicado: (2014)

Sickness Presence among Health Care Professionals: A Cross Sectional Study of Health Care Professionals in Slovenia
por: Skerjanc, Alenka, et al.
Publicado: (2020)

Polymorphisms in folate pathway and pemetrexed treatment outcome in patients with malignant pleural mesothelioma
por: Goricar, Katja, et al.
Publicado: (2014)

Matrix Metalloproteinases Polymorphisms as Prognostic Biomarkers in Malignant Pleural Mesothelioma
por: Štrbac, Danijela, et al.
Publicado: (2017)

The association of genetic factors with serum calretinin levels in asbestos-related diseases
por: Zupanc, Cita, et al.
Publicado: (2023)

Matrix Metalloproteinases Polymorphisms as Baseline Risk Predictors in Malignant Pleural Mesothelioma
por: Strbac, Danijela, et al.
Publicado: (2018)

Evaluation of Matrix Metalloproteinase 9 Serum Concentration as a Biomarker in Malignant Mesothelioma
por: Štrbac, Danijela, et al.
Publicado: (2019)

Association of MiR-126 with Soluble Mesothelin-Related Peptides, a Marker for Malignant Mesothelioma
por: Santarelli, Lory, et al.
Publicado: (2011)

Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis
por: Cui, Ai, et al.
Publicado: (2014)

Extracellular Vesicle Enriched miR-625-3p Is Associated with Survival of Malignant Mesothelioma Patients
por: Goričar, Katja, et al.
Publicado: (2021)

The Influence of Workers’ Health Status on Employers’ Decision-Making During Personnel Restructuring in a Typical Public Limited Enterprise in Slovenia
por: MARGAN, Andrea, et al.
Publicado: (2015)

Diagnostic value of soluble mesothelin-related peptides in pleural effusion for malignant pleural mesothelioma: An updated meta-analysis
por: Gao, Ruiyue, et al.
Publicado: (2019)

Prognostic significance of soluble mesothelin in malignant pleural mesothelioma: a meta-analysis
por: Tian, Long, et al.
Publicado: (2017)

Mesothelin Gene Variants Affect Soluble Mesothelin-Related Protein Levels in the Plasma of Asbestos-Exposed Males and Mesothelioma Patients from Germany
por: Rihs, Hans-Peter, et al.
Publicado: (2022)

Level of mesothelin expression can indicate the prognosis of malignant pleural mesothelioma
por: Feng, Feifei, et al.
Publicado: (2020)

Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma
por: Creaney, Jenette, et al.
Publicado: (2014)

Anti-Mesothelin CAR T cell therapy for malignant mesothelioma
por: Castelletti, Laura, et al.
Publicado: (2021)

Hospital Staff’s Risk of Developing Musculoskeletal Disorders, Especially Low Back Pain
por: Hafner, Nataša Dernovšček, et al.
Publicado: (2018)

Occupational Exposure to Silica Dust in Slovenia is Grossly Underestimated
por: Margan, Andrea, et al.
Publicado: (2023)

Pleural Fluid Mesothelin as an Adjunct to the Diagnosis of Pleural Malignant Mesothelioma
por: Creaney, Jenette, et al.
Publicado: (2014)

Variation rs2235503 C > A Within the Promoter of MSLN Affects Transcriptional Rate of Mesothelin and Plasmatic Levels of the Soluble Mesothelin-Related Peptide
por: Silvestri, Roberto, et al.
Publicado: (2020)

A serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice
por: Linch, Mark, et al.
Publicado: (2014)

Improved survival after introduction of chemotherapy for malignant pleural mesothelioma in Slovenia: Population-based survey of 444 patients
por: Kovac, Viljem, et al.
Publicado: (2012)

Pilot Study to Evaluate Serum Soluble Mesothelin-Related Peptide (SMRP) as Marker for Clinical Monitoring of Pleural Mesothelioma (PM): Correlation with Modified RECIST Score
por: Grosso, Federica, et al.
Publicado: (2021)

Homologous Recombination Repair Polymorphisms and the Risk for Osteosarcoma
por: Goričar, Katja, et al.
Publicado: (2015)

Hitting the Bull’s-Eye: Mesothelin’s Role as a Biomarker and Therapeutic Target for Malignant Pleural Mesothelioma
por: Yeo, Dannel, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1v4bge24625pdtck98o9neoevd